What is meant by intention to treat analysis? Survey of published randomised controlled trials

British Medical Journal

Volumn 319, Issue 7211, 1999, Pages 670-674

  Hollis, Sally ^a   Campbell, Fiona ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0033546995     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.319.7211.670     Document Type: Article

References (39)

1. Fisher LD, Dixon DO, HersonJ, Frankowski RK, Hearon MS, Pearce KE. Intcntion to treat in clinical trials. In: Pcarce KE, ed. Statistical issues in drug research mid dn-ehpment. New York: Marcel Dekker, 1990:331 -50.
2. Bollini P, Pampallona S, Tibaldi G, Kupclnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dobe-effect relationships in randomised clinical trials. BrJPsychiatry 1999;174:297-300.
3. European Coronary Surgery Study Croup. Coronary-artery b)pass surgery in stable angina pectoris: Survival at two ) ears, lancet 1979;i:889-93.
4. Roland M, Torgerson DJ. Understanding controlled trials. What are pragmatic trials?. BMJ 199S;316:285.
5. Lewis JA, Macliin D. Intention 10 treat-who should use ITT? BrJ Cancer 1993;6S:G 17-50.
6. Issues in trial reporting. Bandolier 1996:3:6-7.
7. Begg C, Cho M, Eastwood S, I lorton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statemenLAAM 1996;276:637-9.
8. Cochrane Controlled Trials Register. Cochrane library. Cochrane Collaboration. Oxford: Update Software, 1997.
9. Spmance SL, Rea TL, Yhoming C, Tucker R, Saltzman R, Boon R. Penciclour cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborate Study Groupj.tUA 1997;277:137-J-9.
10. Fazekas F Deisenliammer F, Strasser-Fuchs S, Naliler G, Mamou B. Randomised placebo controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitdng multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Ltmcel 1997;349:5S9-93.
11. CAESAR Coordinating Committee. Randomised trau of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with H1V-1 infection: tlic CAESAR trial. Lancet 1997:319:1413-21.
12. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lcmcel 1997;350:535-40.
13. Rutgeerts P, Rauws E, Wara P, Swain P, Hoos A, Solleder E, et al. Randomised trial of single and repeated fibrin glue compared with injection of polidocanol treatment of bleeding peptic ulcer. Lancet 1997;350:692-6.
14. N'ashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal auograft recipients. CHIB 201 International Study Group. Lancet 1997:350:1193-8.
15. Jacobson JM, Greenspan JS, SpritzerJ, Ketter N', FaheyJL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. A' Engt J Med 1997:336:1487-93.
16. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, et al. Low dose Compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection, \ational Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. A'ingMed 1997336:1641-8.
17. Englund JABaker CJ, Raskino C, McKinney RE, Petric B, Fowler MG, et al.. Zidovudine, didanosine, or both as dic initial treatment for symptomatic HI-infected children. AIDS Clinical Trials Group Study 152 Team. XEnglJMed 1997:336:1704-12.
18. TardifJC, Cote G, LesperanceJ, Bourassa M, Lambert J, Doucet S, et al. Probucol and multivitamins in dic prevention of restenosis after coronar)- angioplasty. Multivitamins and Probuco Study Group. X Engt J Med 1997:337:365-72.
19. Guilhot F, Chastang C, Michallot M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. NEnglJ.Med 1997;37:223-9.
20. Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb CM, Boiling SF, et al. Prcoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. EnglJMed 1997:337:1785-91.
21. Liem MS, van der Graaf Y, van Steensel CJ, Boelhouwer RU, Clevers GJ, Meijer W, et al. Comparison of conventional anterior surgery and laparoscopic surgery for inguinal-hernia repair. A' Engt J Med 1997:336:1541-7.
22. O'Connor 11, Broadbent JA, Magos AI, McPherson K. Medical Research Council randomised trial of endometrial resection versus hysterectomy in management of menorrhagia. Lawrr 1997:349:879-901.
23. Daly S, Mills JL, Molloy AM, Conley IM, Lee YJ, Kirke PN, et al. Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. Lancet 1997:350:1662-5.
24. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering oflow-density lipoprotein cholesterol levels and lowdose anticoagulation on obstructive changes in saphcnous-vein coronary-artery bypass grafts. A'EnglJMed 1997036:153-62.
25. Schulz KF, Grimes DA, Airman DG, Hayes RJ. Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology. DMJ 1996:312:742-4.
26. Guyatt GH, Sackett DL, Cook DJ. Users'guides to dic medical Iiterature.2. How to use an article about therapy or prevention. A. Are the results of dic study vaIid? JAMA 1993;270:259S-601.
27. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research, InlJEfiidemiol 1992:21:837-41.
28. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. A' EnglJ Med 19SO;303:1038-41.
29. Cuzick J, Edwards R, Segnan X. Adjusting for non-compliance and contamination in randomized clinical trials. Slat Med 1997;! 6:1017-29.
30. Efron B, Feldman D. Compliance as an explanatory variable in clinical trials.ylm StatAssoc 1991;86:9-17.
31. Goetghebeur EJ. Shapiro SH. Analysing non-compliance in clinical trials: ediical imperative or mission impossible? Slat Med 1996;15:2813-26.
32. Sommer A, Zeger SL, On estimating efficacy from clinical trials. Stat Med 1991:10:45-52.
33. Senn SJ. Statistical issues in drug dmhpment, Chichester: Wiley, 1997.
34. Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB III, Werner JA, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. XEnglJMed 1997:337:740-7.
35. Little RA, Rubin DB. Statistical analysis with missing data. New York: WiIey, 1987.
36. Choi SC, Lu IL. Effect of non-random missing data mechanisms in clinical trials. Slat Med 1995;14:2675-84.
37. Lagakos SW, Lim LL, Robins JM. Adjusting for early treatment termination in comparative clinical trials. Slat Med 1990;9:1417-24.
38. Sackett DL, Richardson U'S, Rosenberg W'S, Haynes RB. Evidence-based medicine. New York: Churchill Livingstone, 1997.
39. Litde R, Yau L. Intent-to-treat analysis for longitudinal studies with dropouts. Biomrlria 1996:52:1324-33.